HUYABIO International, a global developer of novel biopharmaceutical product opportunities originating in China, announced on Tuesday that it has treated its first patient in a pivotal trial aimed at measuring the safety and efficacy of HBI-8000 combined with Bristol Myers Squibb's anti-PD-1, antibody Opdivo (nivolumab), to treat patients with unresectable or metastatic melanoma.
The multicentre, randomised, double blinded, placebo-controlled Phase 3 trial is named 'Study Comparing the Investigational Drug HBI-8000 Combined with Opdivo vs. Opdivo in Patients with Advanced Melanoma'. It will have a primary outcome of objective response rate and progression-free survival, while secondary outcomes include safety and overall survival.
The trial is to enrol 480 patients from the United States, Europe, Australia, New Zealand and Japan. HBI-8000, an epigenetic immunomodulator, is approved in China to treat lymphoma and metastatic breast cancer.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002